BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND ELK4, SAP1, 2005, ENSG00000158711, P28324 AND Clinical Outcome
23 results:

  • 1. PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
    Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
    Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. clinical Analysis of Pediatric T-Cell Acute Lymphoblastic leukemia Using the MRD-Oriented Strategy System.
    Xue YJ; Wang Y; Lu AD; Jia YP; Zuo YX; Ding MM; Zeng HM; Zhang LP
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):477-483. PubMed ID: 37080879
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia.
    Touzart A; Boissel N; Belhocine M; Smith C; Graux C; Latiri M; Lhermitte L; Mathieu EL; Huguet F; Lamant L; Ferrier P; Ifrah N; Macintyre E; Dombret H; Asnafi V; Spicuglia S
    Haematologica; 2020 Jun; 105(6):1575-1581. PubMed ID: 31537687
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).
    Candoni A; Rambaldi A; Fanin R; Velardi A; Arcese W; Ciceri F; Lazzarotto D; Lussana F; Olivieri J; Grillo G; Parma M; Bruno B; Sora F; Bernasconi P; Saccardi R; Foà R; Sessa M; Bresciani P; Giglio F; Picardi A; Busca A; Sica S; Perruccio K; Zucchetti E; Diral E; Iori AP; Colombo AA; Tringali S; Santarone S; Irrera G; Mancini S; Zallio F; Malagola M; Albano F; Carella AM; Olivieri A; Tecchio C; Dominietto A; Vacca A; Sorasio R; Orciuolo E; Risitano AM; Leotta S; Cortelezzi A; Mammoliti S; Oldani E; Bonifazi F;
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2388-2397. PubMed ID: 31400502
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
    Rodríguez-Veiga R; Montesinos P; Boluda B; Lorenzo I; Martínez-Cuadrón D; Salavert M; Pemán J; Calvillo P; Cano I; Acuña E; Villalba A; Piñana JL; Sanz J; Solves P; Senent L; Vicente A; Sempere A; Cervera J; Barragán E; Jarque I; Torres A; Sanz MA; Sanz GF
    Ann Hematol; 2019 Sep; 98(9):2081-2088. PubMed ID: 31240471
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia].
    Wu J; Lu AD; Zhang LP; Zuo YX; Jia YP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):52-57. PubMed ID: 30704229
    [No Abstract]    [Full Text] [Related]  

  • 7. Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts outcome in T-ALL.
    Touzart A; Lengliné E; Latiri M; Belhocine M; Smith C; Thomas X; Spicuglia S; Puthier D; Pflumio F; Leguay T; Graux C; Chalandon Y; Huguet F; Leprêtre S; Ifrah N; Dombret H; Macintyre E; Hunault M; Boissel N; Asnafi V
    Clin Cancer Res; 2019 Apr; 25(8):2483-2493. PubMed ID: 30659025
    [TBL] [Abstract] [Full Text] [Related]  

  • 8.
    Bond J; Touzart A; Leprêtre S; Graux C; Bargetzi M; Lhermitte L; Hypolite G; Leguay T; Hicheri Y; Guillerm G; Bilger K; Lhéritier V; Hunault M; Huguet F; Chalandon Y; Ifrah N; Macintyre E; Dombret H; Asnafi V; Boissel N
    Haematologica; 2019 Aug; 104(8):1617-1625. PubMed ID: 30655366
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Rituximab in the management of acute lymphoblastic leukemia.
    Levato L; Molica S
    Expert Opin Biol Ther; 2018 Feb; 18(2):221-226. PubMed ID: 29310477
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.
    Canaani J; Savani BN; Labopin M; Huang XJ; Ciceri F; Arcese W; Koc Y; Tischer J; Blaise D; Gülbas Z; Van Lint MT; Bruno B; Mohty M; Nagler A
    Am J Hematol; 2018 Feb; 93(2):246-253. PubMed ID: 29114918
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Early Natural Killer Cell Reconstitution Predicts Overall Survival in T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.
    Minculescu L; Marquart HV; Friis LS; Petersen SL; Schiødt I; Ryder LP; Andersen NS; Sengeloev H
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2187-2193. PubMed ID: 27664326
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
    Badar T; Kantarjian HM; Nogueras-Gonzalez GM; Borthakur G; Garcia Manero G; Andreeff M; Konopleva M; Kadia TM; Daver N; Wierda WG; Luthra R; Patel K; Oran B; Champlin R; Ravandi F; Cortes JE
    Am J Hematol; 2015 Nov; 90(11):1065-70. PubMed ID: 26299958
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
    Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
    Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. [Prognostic value of absolute monocyte count in chronic lymphocytic leukaemia].
    Szerafin L; Jakó J; Riskó F
    Orv Hetil; 2015 Apr; 156(15):592-7. PubMed ID: 25845318
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Total costs and clinical outcome of hematopoietic stem cell transplantation in adults with leukemia: comparison between reduced-intensity and myeloablative conditioning.
    Suh KJ; Kim I; Lim J; Ha H; Park S; Koh Y; Yoon SS; Park S
    Clin Transplant; 2015 Feb; 29(2):124-33. PubMed ID: 25430486
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. L-asparaginase: long-term results of a randomized trial of the effect of additional 3 doses during consolidation treatment in the Indonesian WK-ALL-2000 protocol.
    Widjajanto PH; Sumadiono S; Purwanto I; Sutaryo S; Veerman AJ
    J Pediatr Hematol Oncol; 2013 Nov; 35(8):597-602. PubMed ID: 23389497
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.
    Aricò M; Schrappe M; Hunger SP; Carroll WL; Conter V; Galimberti S; Manabe A; Saha V; Baruchel A; Vettenranta K; Horibe K; Benoit Y; Pieters R; Escherich G; Silverman LB; Pui CH; Valsecchi MG
    J Clin Oncol; 2010 Nov; 28(31):4755-61. PubMed ID: 20876426
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Myeloproliferative disorders.
    Levine RL; Gilliland DG
    Blood; 2008 Sep; 112(6):2190-8. PubMed ID: 18779404
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
    Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringdén O; Hassan M
    Bone Marrow Transplant; 2008 Apr; 41(7):621-5. PubMed ID: 18084338
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Li JP; Zhang T; Zhong J; Chen J
    Hematology; 2007 Apr; 12(2):117-21. PubMed ID: 17454192
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.